Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
ICS/LABA Combination

Fluticasone-Salmeterol

Brand names: Seretide, AirFluSal

A fixed-dose combination inhaler of an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) used for maintenance treatment of asthma and COPD.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Fluticasone suppresses airway inflammation via glucocorticoid receptor activation, while salmeterol produces sustained bronchodilation through beta-2 adrenoceptor stimulation and airway smooth muscle relaxation.

Prescribing in practice

  • A long-acting beta-2 agonist must never be used without a concomitant inhaled corticosteroid in asthma, which this combination ensures; it is for maintenance and not for relief of acute symptoms.
  • Rinse the mouth after use to reduce oral candidiasis and hoarseness.
  • In COPD, weigh the recognised increased risk of pneumonia associated with inhaled corticosteroid use.

Monitoring

Monitor symptom control, exacerbation frequency, inhaler technique and, in children, growth on long-term therapy.

Counselling the patient

  • Use it regularly as a preventer and keep a separate fast-acting reliever for sudden symptoms.
  • Rinse your mouth and spit out after each dose.
  • Report a persistent cough, fever or worsening breathlessness.

Evidence & guidelines

Combination ICS/LABA inhalers are recommended in asthma and COPD guidance for patients inadequately controlled on inhaled corticosteroid alone.

Reference: GINA Guidelines 2024; NICE NG80; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways